Sylvester Stallone and TRT: The Documented Public Record

By
Published Updated Last reviewed
Hormone therapy clinical care image for Sylvester Stallone and TRT: The Documented Public Record

The Public Timeline

Sylvester Stallone's connection to hormone therapy entered the public record not through a planned disclosure but through an airport. In February 2007, Australian customs officials found 48 vials of Jintropin (somatropin/HGH) in Stallone's luggage upon his arrival in Sydney. Stallone did not deny possession. He was charged under Australia's Customs Act and ultimately fined A$10,600 after pleading guilty in May 2008 through his lawyer.

What followed was unusual for a celebrity caught in a pharmaceutical controversy: rather than retreating, Stallone leaned into the conversation. In a January 2008 interview with Time magazine, he stated plainly that HGH "is nothing" and described testosterone as something he had used under medical supervision. "Everyone over 40 years old would be wise to investigate it," he told Time, "because it increases the quality of your life."

By the time he was filming The Expendables franchise (2010 to 2014) and later Creed (2015), Stallone, then in his mid-to-late 60s, was publicly maintaining a physique that drew constant media commentary. He did not hide the pharmaceutical component. In multiple interviews across this period, he referenced hormone optimization as part of his regimen alongside intense weight training.

Stallone continued to discuss his approach to aging openly into his 70s. His Instagram posts regularly showcased training sessions, and in interviews surrounding Tulsa King (2022 to present), he has spoken about maintaining physical capacity. While he has not published a detailed protocol, the core claim, that he uses medically supervised testosterone therapy, has remained consistent across nearly two decades of public statements.

What Is Confirmed vs. What Is Speculated

Confirmed by Stallone himself:

  • Long-term use of testosterone under medical supervision, referenced in multiple interviews from 2008 onward
  • Past use of HGH, confirmed both by the 2007 Australian customs incident and his own public comments
  • The position that hormone therapy is a legitimate medical tool for aging men

Speculated but not publicly confirmed:

  • Specific testosterone formulation (injectable testosterone cypionate vs. enanthate vs. topical gel)
  • Specific dosages or blood level targets
  • Whether HGH use continued after the 2008 legal resolution
  • Use of any additional compounds (e.g., anastrozole for estrogen management, DHEA, or peptide secretagogues)
  • The identity of his prescribing physician(s)

The HealthRX Medical Team notes that Stallone's public statements have been more forthcoming than most celebrity disclosures in this space. He has not claimed his physique is solely the product of training and diet. That candor, rare among public figures, makes his case more clinically instructive than most.

Clinical Context: TRT in Men Over 60

Testosterone levels in men decline approximately 1 to 2% per year after age 30, a process sometimes called "andropause" though the medical community increasingly uses the term "late-onset hypogonadism." By age 70, a significant proportion of men have testosterone levels below the reference range of 300 to 1 to 000 ng/dL that most labs use.

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, was a landmark moment for TRT safety data. This randomized, double-blind, placebo-controlled trial enrolled 5,246 men aged 45 to 80 with hypogonadism and pre-existing or high risk of cardiovascular disease. The primary finding: testosterone replacement did not increase the incidence of major adverse cardiovascular events compared with placebo. This addressed decades of uncertainty that had made many clinicians hesitant to prescribe.

For men in Stallone's age bracket (late 70s), the clinical picture involves several considerations the HealthRX Medical Team finds worth outlining.

Expected Benefits (Supported by Evidence)

TRT in hypogonadal older men has demonstrated improvements in lean body mass, fat mass reduction, and bone mineral density. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in men 65 and older, found benefits in sexual function, physical function (particularly walking distance), and mood. Bone mineral density improvements were significant enough to be detectable on quantitative CT within 12 months.

These are the benefits most consistent with what Stallone has publicly described: maintained muscle mass, sustained energy, and continued physical capacity well into his 70s.

Monitoring Requirements

TRT is not a set-and-forget prescription, particularly for men over 60. Standard monitoring protocols include:

  • Hematocrit and hemoglobin every 3 to 6 months. Testosterone stimulates erythropoiesis, and hematocrit levels above 54% increase thrombotic risk. This is the most common reason clinicians adjust TRT dosing. The Endocrine Society's 2018 guidelines recommend dose reduction or temporary cessation if hematocrit exceeds this threshold.
  • PSA (prostate-specific antigen) at baseline and periodically thereafter. TRT does not cause prostate cancer based on current evidence, but it can accelerate growth of pre-existing prostate malignancies. The FDA label carries this warning.
  • Estradiol levels. Aromatization of testosterone to estradiol increases with dose and with body fat percentage. Elevated estradiol can cause gynecomastia, water retention, and mood disturbance.
  • Lipid panel. Supraphysiologic testosterone doses tend to suppress HDL cholesterol. Therapeutic-range TRT has a more modest effect, but monitoring remains standard.
  • Liver function (particularly with oral formulations, though injectables bypass first-pass hepatic metabolism).

The HGH Question

Stallone's confirmed past HGH use adds a second clinical layer. Growth hormone in adults operates through a different mechanism than testosterone. GH stimulates hepatic production of insulin-like growth factor 1 (IGF-1), which mediates most of its anabolic effects: increased protein synthesis, lipolysis, and collagen turnover.

The evidence base for HGH in aging adults is far less favorable than for TRT. A meta-analysis in the Annals of Internal Medicine found that while GH therapy in older adults produced modest increases in lean mass (about 2 kg) and decreases in fat mass, it also significantly increased rates of edema, arthralgias, carpal tunnel syndrome, and glucose intolerance. The FDA has not approved GH for anti-aging purposes, and its use for this indication remains off-label and controversial.

The HealthRX Medical Team draws a clear distinction here: Stallone's confirmed TRT use falls within established, guideline-supported medical practice for hypogonadal men. His confirmed past HGH use occupies a much grayer clinical and legal zone.

Why This Case Matters Clinically

Stallone's public record represents something unusual: a nearly 20-year documented relationship with TRT that spans ages roughly 60 to 79. Most clinical trial data on TRT in older men covers 1 to 3 years of follow-up. The TRAVERSE trial ran for a mean of 33 months. Long-term observational data beyond 5 years remains limited.

This is not to suggest that one celebrity's experience substitutes for clinical evidence. It does not. But Stallone's visibility has shaped public perception of TRT in older men in ways that carry real clinical consequences. The HealthRX Medical Team regularly encounters patients who reference celebrity examples when discussing hormone therapy with their physicians. Some arrive with unrealistic expectations. Others arrive having delayed a conversation about legitimate hypogonadal symptoms because they associated TRT exclusively with bodybuilding or performance enhancement.

The reality, supported by TRAVERSE and the TTrials, is more measured. TRT in appropriately diagnosed hypogonadal men over 60 can meaningfully improve quality of life metrics. It requires ongoing monitoring. It is not a cosmetic shortcut, and the physique Stallone maintains also reflects decades of serious resistance training, a detail sometimes lost in media coverage.

At a glance

  • Status: Stallone has publicly confirmed long-term TRT use under medical supervision since at least 2008
  • HGH: Past use confirmed via 2007 Australian customs incident and his own statements; current HGH status unknown
  • Clinical relevance: His case represents one of the longest publicly documented celebrity TRT timelines, spanning ages ~60 to 79
  • Medical consensus on TRT in older men: The 2023 TRAVERSE trial found no increased cardiovascular risk in hypogonadal men; the TTrials showed benefits in sexual function, physical function, bone density, and mood
  • Key monitoring: Hematocrit, PSA, estradiol, and lipids require regular follow-up on TRT
  • The HealthRX Medical Team take: Stallone's TRT use is consistent with guideline-supported therapy for age-related hypogonadism. His openness has been net-positive for public awareness, though his results also reflect elite-level training that TRT alone does not replicate

Frequently asked questions

›
›
›
›
›
›

References